



**The Perfect Excipient Pairing for LoxaSperse®**

**PCCA # 30-4894**

## Give sinus preparations a boost.

**XyliFos** is an excipient base developed to be used in combination with LoxaSperse to maximize the solubilizing/dispersing properties. See PCCA Document #98491 for detailed LoxaSperse information.

### BENEFITS

- XyliFos is a synergistic/booster for LoxaSperse, and is designed to be the perfect excipient pairing for LoxaSperse.
- Using XyliFos in formulations allows for improved overall efficiency and performance of the preparation due to its synergy with LoxaSperse
  - Improves the solubilizing/dispersing characteristics of LoxaSperse by using a new technology – cyclodextrin complex.
  - Improves formulation substantivity (mucosal adhesiveness) as well as moisturization
  - Supports the activity of antimicrobials, antivirals, anti-inflammatories and antihistamines used in formulations through a unique patent-pending EGCg–cyclodextrin complex
- Combining XyliFos with LoxaSperse allows for the use of lower levels of LoxaSperse in formulations (10% versus a minimum of 25% without XyliFos), which is more cost effective – in some cases, saving up to 50% on the cost of preparing a prescription.



### RELATED SPECIALTIES

- Ear, nose and throat specialists
- General practice
- Allergists

### COMMONLY COMPOUNDED WITH

- Antifungals
- Antibiotics
- Corticosteroids
- Antihistamines
- Anesthetics

*Continued on the next page*



## FORMULATED WITHOUT

- Dyes
- Egg
- Gluten
- Nuts
- Preservatives
- Soy

## FORMULA EXAMPLES

- **PCCA Formula #11603**  
Budesonide 0.5 mg Capsules Size #1 (XyliFos/LoxaSpers<sup>™</sup>)
- **PCCA Formula #11623**  
Amphotericin B 10 mg Capsules Size #1 (XyliFos/LoxaSpers<sup>e</sup>)
- **PCCA Formula #11624**  
Clindamycin 50 mg Capsules Size #1 (XyliFos/LoxaSpers<sup>e</sup>)
- **PCCA Formula #11983**  
Gentamicin 80 mg/Mupirocin 30 mg/Edetate Disodium 15 mg Capsules Size #1 (XyliFos/LoxaSpers<sup>e</sup>)
- **PCCA Formula #11610**  
Gentamicin 80 mg Capsules Size #1 (XyliFos/LoxaSpers<sup>e</sup>)
- **PCCA Formula #11742**  
Levofloxacin 100 mg/Betamethasone 0.5 mg Capsules Size #1 (XyliFos/LoxaSpers<sup>e</sup>)

- **PCCA Formula #11917**  
Tobramycin 100 mg Capsules Size #1 (XyliFos/LoxaSpers<sup>e</sup>)
- **PCCA Formula #11741**  
Tobramycin 125 mg/Itraconazole 40 mg/Budesonide 0.6 mg Capsules Size #00 (XyliFos/LoxaSpers<sup>e</sup>)
- **PCCA Formula #11745**  
Gentamicin 80 mg/Mupirocin 20 mg/Betamethasone 0.75 mg Capsules Size #1 (XyliFos/LoxaSpers<sup>e</sup>)
- **PCCA Formula #11973**  
Doxycycline 20 mg/Phenytoin 20 mg/Lidocaine HCl 10 mg/Misoprostol 0.024 mg Wound Care Capsules Size #1 (XyliFos/LoxaSpers<sup>e</sup>)
- **PCCA Formula #11615**  
Gabapentin 300 mg/Ketamine HCl 50 mg/Lidocaine 30 mg/Prilocaine 30 mg Wound Care Capsules Size #00 (XyliFos/LoxaSpers<sup>e</sup>)

## FREQUENTLY ASKED QUESTIONS

### How is XyliFos used in formulations?

It is recommended to use LoxaSpers<sup>e</sup> at 10% of the capsule volume, then QS with XyliFos. The minimum amount of XyliFos needed in a formulation is 15%.

### Can existing LoxaSpers<sup>e</sup> formulas be converted to use the combination?

Yes. Visit the Members-Only Website > Formula Tools and use the Capsule Calculator to assist in calculations.

*Continued on the next page*

### ALSO AVAILABLE

## PCCA LoxaSpers<sup>®</sup>

LoxaSpers<sup>e</sup> is an innovative powder excipient base that improves dispersibility and solubility of APIs used for nebulization and irrigation. Because it's dispensed as a dry powder, it has a prolonged beyond-use date.

**PCCA #30-4701**



## FREQUENTLY ASKED QUESTIONS *(continued)*

### What are the cost savings associated with using XyliFos versus LoxaSperse alone?

Below are two formula examples showing the cost savings.\*

Example 1:

**PCCA Formula #10341:** Budesonide 0.5 mg Capsules  
Size #1 (LoxaSperse)

Cost: \$137.20/100 capsules

**PCCA Formula #11603:** Budesonide 0.5 mg Capsules  
Size #1 (XyliFos/LoxaSperse)

Cost: \$57.79/100 capsules

**Savings:** \$79.41/100 capsules when combining XyliFos with LoxaSperse

Example 2:

**PCCA Formula #10610:** Glutathione 200 mg Capsule  
Size #0 (Loxasperse)

Cost: \$151.10/100 capsules

**PCCA Formula #11618:** Glutathione 200 mg Capsule  
Size #0 (XyliFos/Loxasperse)

Cost: \$114.88/100 capsules

**Savings:** \$36.22/100 capsules when combining XyliFos with LoxaSperse

\* Cost savings listed are estimates and can vary depending on the bulk size of chemicals purchased as unit price often changes with quantity purchased.

## CONTROLLED STUDIES

1. Technical Report: Characterization of the Physical and Microbiological Properties of XyliFos
2. Technical Report: Microbiological Quality of XyliFos and LoxaSperse 10% in XyliFos Dispersions Evaluated by Mikrocount<sup>®</sup> Combi
3. Technical Report: Evaluation of the Safety and Toxicological Profile of XyliFos in the Nasal Mucosa

To see all of our XyliFos studies in depth, visit [PCCA Document #99077](#).

## PLEASE NOTE

*Always make sure you have checked the PCCA formula database and are following the most up-to-date version of a formula, as changes are continually made to existing formulations to provide the highest quality. The formulas and/or statements listed are provided for educational purposes only. They are compounding ideas that have commonly been requested by physicians and have not been evaluated by the Food and Drug Administration. Formulas and/or material listed are not to be interpreted as a promise, guarantee, or claim of therapeutic efficacy or safety. The information contained herein is not intended to replace or substitute for conventional medical care or encourage its abandonment. Every patient is unique, and formulas should be adjusted to meet their individual needs.*